文献速递妇科肿瘤

阿维鲁单抗治疗复发性或难治性卵巢癌的疗效与安全性:JAVELIN实体瘤试验1b期结果

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

该研究为1b期开放标签试验的扩展队列,纳入125例既往接受含铂化疗的晚期卵巢癌患者,每2周给予阿维鲁单抗10 mg/kg。确认客观缓解率为9.6%(95%CI 5.1%-16.2%),1年无进展生存率10.2%,中位总生存期11.2个月,≥3级治疗相关不良事件发生率为7.2%,无治疗相关死亡。

要点

  • 确认客观缓解率9.6%(12/125),含完全缓解1例(0.8%)和部分缓解11例(8.8%)。
  • 中位总生存期11.2个月(95%CI 8.7-15.4),1年无进展生存率10.2%(95%CI 5.4%-16.7%)。
  • ≥3级治疗相关不良事件发生率7.2%(9例),无治疗相关死亡。

核心结论

  • 阿维鲁单抗在经多线治疗的复发性或难治性卵巢癌患者中显示出抗肿瘤活性和可接受的安全性。

研究设计与样本

  • JAVELIN实体瘤试验(1b期、开放标签研究)的扩展队列,纳入125例既往接受含铂化疗的晚期卵巢癌患者,入组时间为2013年11月6日至2015年8月27日。
  • 患者接受阿维鲁单抗10 mg/kg每2周一次,直至疾病进展、不可接受的毒性反应或退出研究。
  • 统计学分析时间为2016年12月31日至2018年10月9日。

主要发现

  • 125例女性患者中位年龄62.0岁(范围27-84岁),既往针对晚期疾病的中位治疗线数为3线(范围0-10线)。
  • 患者接受阿维鲁单抗的中位治疗时间为2.8个月(范围0.5-27.4个月),中位随访时间为26.6个月(范围16-38个月)。
  • 确认客观缓解12例(9.6%;95%CI 5.1%-16.2%),其中完全缓解1例(0.8%)、部分缓解11例(8.8%)。
  • 1年无进展生存率为10.2%(95%CI 5.4%-16.7%),中位总生存期为11.2个月(95%CI 8.7-15.4个月)。
  • 输注相关反应发生于25例(20.0%);其他常见治疗相关不良事件(任何级别发生率≥10%)包括乏力17例(13.6%)、腹泻15例(12.0%)、恶心14例(11.2%)。

关键数值与推荐

  • ≥3级治疗相关不良事件发生于9例(7.2%),其中仅脂肪酶升高(3例,2.4%)在超过1例患者中发生。
  • 任何级别的免疫相关不良事件发生于21例(16.8%)。
  • 未发生治疗相关死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. OBJECTIVE: To assess the efficacy and safety of avelumab, an anti-programmed death-ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: In an expansion cohort of a phase 1b, open-label study (JAVELIN Solid Tumor), 125 patients with advanced ovarian cancer who had received chemotherapy including a platinum agent were enrolled between November 6, 2013, and August 27, 2015. Statistical analysis was performed from December 31, 2016, to October 9, 2018. INTERVENTION: Patients received avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study. MAIN OUTCOMES AND MEASURES: Prespecified end points in this cohort included confirmed best overall response (per Response Evaluation Criteria In Solid Tumors, version 1.1), immune-related best overall response, duration of response, progression-free survival, overall survival, results of programmed death-ligand 1 expression-based analyses, and safety. RESULTS: A total of 125 women (median age, 62.0 years [range, 27-84 years]) who had received a median of 3 prior lines of treatment (range, 0-10) for advanced disease were enrolled in the study. Patients received avelumab for a median of 2.8 months (range, 0.5-27.4 months), with a median follow-up of 26.6 months (range, 16-38 months). A confirmed objective response occurred in 12 patients (9.6%; 95% CI, 5.1%-16.2%), including a complete response in 1 patient (0.8%) and a partial response in 11 patients (8.8%). The 1-year progression-free survival rate was 10.2% (95% CI, 5.4%-16.7%) and median overall survival was 11.2 months (95% CI, 8.7-15.4 months). Infusion-related reactions occurred in 25 patients (20.0%). Other frequent treatment-related adverse events (any grade event occurring in ≥10% of patients) were fatigue (17 [13.6%]), diarrhea (15 [12.0%]), and nausea (14 [11.2%]). Grade 3 or higher treatment-related adverse events occurred in 9 patients (7.2%), of which only the level of lipase increased (3 [2.4%]) occurred in more than 1 patient. Twenty-one patients (16.8%) had an immune-related adverse event of any grade. No treatment-related deaths occurred. CONCLUSIONS AND RELEVANCE: Avelumab demonstrated antitumor activity and acceptable safety in heavily pretreated patients with recurrent or refractory ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01772004.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Disis ML, Taylor MH, Kelly K, et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019. PMID: 30676622. doi:10.1001/jamaoncol.2018.6258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。